MARKET

ORXOF

ORXOF

Orexo Ab
OTCQX
1.550
NaN%
Opening 09:30 10/06 EDT
OPEN
--
PREV CLOSE
1.550
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
2.900
52 WEEK LOW
1.550
MARKET CAP
50.65M
P/E (TTM)
0.637
1D
5D
1M
3M
1Y
5Y
1D
Orexo launches 250 MSEK rights issue to fund pipeline and strengthen finances
TipRanks · 9h ago
Orexo convenes EGM to approve rights issue and capital authorizations
TipRanks · 9h ago
Orexo Resubmits High-Dose Opioid Overdose Rescue Drug IZIPRY for FDA Review
TipRanks · 09/29 14:03
Orexo Wins FDA Green Light to Advance Needle‑Free Anaphylaxis Treatment OX640
TipRanks · 09/14 06:33
Orexo Wins BARDA Funding Boost to Extend OX390 Overdose Rescue Development
TipRanks · 09/10 06:34
Orexo CFO Fredrik Järrsten to Step Down as Company Streamlines Operations
TipRanks · 09/01 19:32
Orexo Moves to Settle U.S. DOJ Probe With Non‑Prosecution Deal
TipRanks · 08/31 06:34
Orexo AB Earnings Call: Science Progress, Cash Strain
TipRanks · 07/17 00:07
More
About ORXOF
Orexo AB is a Sweden-based company active within the pharmaceutical industry. It focuses primarily on the development of new, patented drugs by combining documented substances with technologies, and the new treatments for respiratory and inflammatory diseases. The Company has four commercialized products, several projects developed in partnership, as well as three development programs. The Company's registered products are: Abstral for the treatment of break through cancer pain, sold by ProStrakan Group plc in Europe, the United States and Canada; the sleeping pill Edluar, sold by Meda in the United States and Canada; as well as two products for the diagnosis of Helicobacter pylori which are being marketed by the subsidiary, Kibion AB. The Company operates through subsidiaries: Pharmacall AB, Noster System AB, Orexo UK, and Pharmakodex Ltd, among others. In December 2013, Kyowa Hakko Kirin Co., Ltd (KHK), with the licensed right to Abstral, commenced the launch of it in Japan.

Webull offers Orexo AB stock information, including OTCQX: ORXOF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ORXOF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ORXOF stock methods without spending real money on the virtual paper trading platform.